Klaus Binder
Directeur Général chez Binder Associates GmbH
Profil
Klaus Binder is the founder of Binder Associates GmbH.
He is currently the Chairman of Abalos Therapeutics GmbH.
Previously, he served as the Chairman-Supervisory Board of amaxa GmbH, Director of Natrix Separations, Inc., and Principal at Boehringer Ingelheim GmbH and Boehringer Ingelheim Pharma GmbH & Co., KG.
Postes actifs de Klaus Binder
| Sociétés | Poste | Début |
|---|---|---|
| Binder Associates GmbH | Directeur Général | - |
Abalos Therapeutics GmbH
 Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Président | 05/02/2020 |
Anciens postes connus de Klaus Binder
| Sociétés | Poste | Fin |
|---|---|---|
NATRIX Separations, Inc.
 NATRIX Separations, Inc. Medical SpecialtiesHealth Technology NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada. | Directeur/Membre du Conseil | 01/09/2017 |
Boehringer Ingelheim Pharma GmbH & Co., KG
 Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co., KG is a company that operates research-based pharmaceutical companies and serves. Boehringer Ingelheim Pharma GmbH & Co., KG is based in Ingelheim, Germany. The German company was founded in 1885 by Albert Boehringer. The CEO is Hubertus von Baumbach. | Corporate Officer/Principal | - |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | - |
amaxa GmbH
 amaxa GmbH Miscellaneous Commercial ServicesCommercial Services amaxa GmbH researches gene transfer and gene-based medicines to develop causal therapies for the treatment of severe diseases. It focuses on high-end applications for non-viral delivery of genes and transfer of other charged substrates into cells. The company was founded in 1998 and is headquartered in Cologne, Germany. | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
amaxa GmbH
amaxa GmbH Miscellaneous Commercial ServicesCommercial Services amaxa GmbH researches gene transfer and gene-based medicines to develop causal therapies for the treatment of severe diseases. It focuses on high-end applications for non-viral delivery of genes and transfer of other charged substrates into cells. The company was founded in 1998 and is headquartered in Cologne, Germany. | Commercial Services |
NATRIX Separations, Inc.
NATRIX Separations, Inc. Medical SpecialtiesHealth Technology NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada. | Health Technology |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Boehringer Ingelheim Pharma GmbH & Co., KG
Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co., KG is a company that operates research-based pharmaceutical companies and serves. Boehringer Ingelheim Pharma GmbH & Co., KG is based in Ingelheim, Germany. The German company was founded in 1885 by Albert Boehringer. The CEO is Hubertus von Baumbach. | Health Technology |
| Binder Associates GmbH | |
Abalos Therapeutics GmbH
Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Health Technology |
